Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

Human NSCLCs with activating mutations in EGFR frequently respond to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib but responses are not durable as tumors acquire resistance. Secondary mutations in EGFR (T790M) or upregulation of the MET kinase are found in over 50% of resi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhang, Zhenfeng, Lee, Jae Cheol, Lin, Luping, Olivas, Victor, Au, Valerie, LaFramboise, Thomas, Abdel-Rahman, Mohamed, Wang, Xiaoqi, Levine, Alan D., Rho, Jin Kyung, Choi, Yun Jung, Choi, Chang-Min, Kim, Sang-We, Jang, Se Jin, Park, Young Soo, Kim, Woo Sung, Lee, Dae Ho, Lee, Jung-Shin, Miller, Vincent A., Arcila, Maria, Ladanyi, Marc, Moonsamy, Philicia, Sawyers, Charles, Boggon, Titus J., Ma, Patrick C., Costa, Carlota, Taron, Miquel, Rosell, Rafael, Halmos, Balazs, Bivona, Trever G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3408577/
https://ncbi.nlm.nih.gov/pubmed/22751098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.2330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados